Perbandingan Kadar Vitamin D Pada Penderita HIV AIDS Yang Mendapat ARV Satu Tahun Dan Yang Belum Mendapat ARV
53
DAFTAR PUSTAKA
1. Djoerban Z, Djauzi. HIV/AIDS di Indonesia. Dalam: Buku Ajar Ilmu
Penyakit Dalam, Jilid III, Edisi V, Pusat Penerbit Departemen Ilmu
Penyakit Dalam FKUI, Jakarta: 2009 November; 2861-8.
2. Nasronudin. Penatalaksanaan Klinis Infeksi HIV & AIDS. Dalam: HIV
AIDS, Pendekatan Biologi Molekuler, Klinis dan Sosial. Barakbah J,
Soewandojo E, Suharto, Hardi U, Astuti WD. Universitas Airlangga.
Surabaya: 2007; 31-43.
3.
Fauci AS and Lane HC. Human Immunodeficiency Virus disease: AIDS
and related disorders. In: Kasper DL, Fauci AS, Longo DL, Braunwald
E, Hauser SL, Jameson JL (eds). Harrison’s Principles of Internal
Medicine Volume 1. 17th Edition. New York: Mc Graw Hill Companies.
2008; 1076-98.
4. U.S. Agency for International Development (2010). HIV/AIDS Health
Profile.
http://www.usaid.gov/our_work/global_health/aids/Countries/asia/indone
sia.html
5. United Nations Programme on HIV/AIDS. Global report: UNAIDS report
on the Global AIDS Epidemic 2012.
6. Kementerian
Kesehatan
Republik
Indonesia.
Direktorat
Jenderal
Pengendalian Penyakit dan Penyehatan Lingkungan (Ditjen P2PL).
Laporan Perkembangan HIV/AIDS. 2012.
7. Kementrian Kesehatan Republik Indonesia. Informasi Pengendalian
Penyakit Penyehatan Lingkungan. Direktorat Jenderal Pengendalian
Penyakit dan Penyehatan Lingkungan. 2013.
Universitas Sumatera Utara
54
8. Dinkes
Provinsi
Penanggulangan
Sumatera
Penyakit
Utara.
Kasus
Menular
dan
HIV/AIDS.
penyehatan
Bidang
Lingkungan
(P2MPL). 2013.
9. Mehta S, Giovannuci E, Mugusi FM et al. Vitamin D Status of HIVInfected Women and Its Association with HIV Disease Progression,
Anemia and Mortality. Plos One. 2010; 5:e8770.
10. Kementerian
Kesehatan
Republik
Indonesia.
Direktorat
Jenderal
Pengendalian Penyakit dan Penyehatan Lingkungan (Ditjen P2PL).
Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi
Antiretroviral pada Orang Dewasa dan Remaja. 2011.
11. World Health Organization. Antiretroviral Therapy for HIV Infection in
Adults and Adolescents: Recommendations for a Public Health
Approach. 2010.
12. Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;357:266-8.
13. Holick MF. Sunlight and Vitamin D for Bone Health and Prevention of
Autoimmune Dissease, Cancers, and Cardiovascular Dissease. Am J Clin
Nutr. 2004; 80(suppl):1678S– 88S.
14. Carolien JP, Bos M, Oyen WJG, et al. Vitamin D Deficiency Among
HIV-1-Infected Individuals in The Netherlands: Effects of Antiretroviral
Therapy. Aids Research and Human Retroviruses. 2008; 24: 1375-82.
15. Botella AC, Florence E, Lynen L, et al. Decrease of Vitamin D
Concentration in Patients with HIV Infection on a Non-nucleoside
Reverse transcriptase Inhibitor-Containing regimen. 2010.
16. Melamed ML, Michos ED, Post W, et al. 25-hydroxyl Vitamin D Levels
and Risk Mortaliy in The General Populations. Arch Intern Med. 2008;
168:1629–37.
17. Ellfolk M, Norlin M, Gyllensten, et al. Regulation of Human Vitamin D
(3) 25-Hydroxylases in Dermal Fibroblasts and Protease Cancer LNCaP
Cells. Mol Pharmacol. 2009; 75:1392-99.
18. Paul TV, Asha HS, Thomas N, et al. Hypovitaminosis D and Bone
Mineral Density in Human Immunodeficiency Virus-Infected Men from
Universitas Sumatera Utara
55
India, with or without Antirretroviral Therapy. Endocrine Practice. 2010;
16: 547-53.
19. Cozzolino M, Vidal M, Arcidiacono MV, et al. HIV-Protease Inhibitors
Impair Vitamin D Bioactivation to 1,25-Dihydroxyvitamin D. AIDS.
2003; 17: 513-20.
20. Chorol T, Das S, Choudhry S, Ramachandran VG, Ranga GS,
Bhattacharya SN, Bhadoria DP. Absolute Lymphocyte Count: A useful
Surrogate Marker to Initiate Antiretroviral Therapy in Resource Poor
Settings. Asian Pacific Journal of Tropical Disease. 2012; 744-7.
21. Fauci AS. HIV and AIDS: 20 Years of Science. Nature Medicine. 2008;
9(7): 839-43.
22. Levy JA. HIV Pathogenesis: 25 Years of Progress and Persistent
Challenges. AIDS. 2009; 23: 147-60.
23. Montagnier L. 25 Years After HIV Discovery: Prospects for Cure and
Vaccine. Nobel Lecture, World Foundation for AIDS Research and
Prevention, UNESCO. 2008.
24. Belasio FE, Raimondo M, Suligoi B, Butto S. HIV Virology and
Pathogenetic Mechanism of Infection: A Brief Overview, Ann 1st Super
Sanita. 2010; 46(1):5-14.
25. Liu PT, Stenger S, Tang DH, et al. Cutting Edge: Vitamin D Mediated
Human Antimicrobial Activity Against Mycobacterium Tuberculosis is
Dependent on The Induction of Cathelicidin. J Immunol. 2007;179:206063.
26. World Health Organization, Regional Office for South-East Asia.
Management of HIV Infection and Antiretroviral Therapy in Adults and
Adolescents. A Clinical Manual. 2007.
27. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et
al. Metabolic Abnormalities and Cardiovascular Disease Risk Factors in
Adults
With
Human
Immunodeficiency
Virus
Infection
and
Lipodystrophy. Clin Infect Dis. 2001; 32(1):130-9.
Universitas Sumatera Utara
56
28. World Health Organization (b). WHO Case Definitions of HIV and
Revised Clinical Staging and Immunological Clasification of HIVRelated Disease in Adult and Children. 2007.
29. World Health Organization (a). Laboratory Guidelines for Enumerating
CD4 T Lymphocytes in the Context of HIV/AIDS. 2007.
30. Wormster GP. The Epidemiologi of HIV and AIDS in AIDS and Other
Manifestation of HIV Infection. New York: Medical College Villaha.
2005.
31. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM,
Katzenstein DA, et al. Antiretroviral Therapy for HIV Infection in 1996.
Recommendations of an
International
Panel.
International
AIDS
Society-USA.
JAMA.
1996;276(2):46-54.
32. Max B, Sherer R. Management of The Adverse of Antiretroviral Therapy
and Medication Adherence. Clinical Infection Disease. 2000;30 (Suppl
2): S96-116.
33. Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo
AL, et al.
Relationship
Between
HAARTAdherence
and
Adipose
Tissue
Alterations. J Acquir Immune Defic Syndr 2002;31 (Suppl 3):140-4.
34. Jagriti P. Pharmacokinetic Boosting of Zidovudine for HIV Treatment,
Int J of Pharmac and Clin Research. 2012;4(3):31-6.
35. Bouvier G. Protease Inhibitors Can Interfere With Vitamin D
Metabolism. HIV Clinician. 2009;9-10.
36. Hewison M. Vitamin D, Immunity and Human Disease. Clinical Rev
Bone Miner Metabolit. 2010;8:32-39.
37. Adams JS, Liu PT, Chun R, et al. Cutting edge: Vitamin in Defense of
Human Immune Response. Ann N Y Acad Sci. 2007; 1117: 94-105.
38. Rosen CJ. Vitamin D insufficiency. N Engl J Med. 2011;364:248-54
39. Haug
JC,
Aukrust
P,
Haug
E.
Severe
Deficiency of
1,25-
Dihydroxyvytamin D 3 in Human Immunodeficiency Virus Infection:
Universitas Sumatera Utara
57
Association With Immunological Hyperactivity and Only Minor Changes
in Calcium Homeostasis. JCE&M. 1998;83:3832-38.
40. Direktorat Jenderal Pemberantasan Penyakit Menular dan Penyehatan
Lingkungan, Departemen Kesehatan Republik Indonesia. Pedoman
Nasional Perawatan, Dukungan dan Pengobatan Bagi ODHA. Jakarta.
Dep Kes RI. 2003.
41. Spaulding A, Rutherford GW, Siegfried N. Tenofovir or Zidovudine in
Three-Drug Combination Therapy with One Nucleoside Reverse
Transcriptase Inhibitor and One Non-Nucleoside Reverse Transcriptase
Inhibitor for Initial Treatment of HIV Infection in Antiretroviral-Naive
Individuals. Wiley. Cochrane Collaboration. 2011;2:1-28.
42. Ramayo E, Moreno MPG, Macias J, et al. Relationship Between
Osteopenia, Free Testosterone, and Vitamin D Metabolite Levels in HIVInfected Patients With and Without Highly Active Antiretroviral Therapy.
AIDS Research and Human Retroviruses. 2005;2:915-21.
43. Liz H et al. Vitamin D Deficiency is Common Among HIV Positive
People and Is Associated with NNRTI Use, Black Race and Sunning.
2009.
44. Viard JP et al. Vitamin D and Clinical Disease Progression in HIV
Infection: Results from The EuroSIDA Study. AIDS. 2011.
45. Chakborty H, Newman JE, Woelk G, Foday H, Peres JI. Antiretroviral
Therapy Initiation and CD4 Progression Over time Among HIV Infected
Adults in Centra Africa. Int J of Med and Public Health. 2011; 1(4):3-11.
46. Gazzard B. What We Know So Far. AIDS. 1996;10(Suppl 1):S3-7.
47. Childs K, Kadis C, Baranch-Elliman W. Vitamin D and Calcium
Supplements
Reverse
The
Secondary
Hyperparathyroidsm
That
Commonly Occurs in HIV Patients on TDF-Containing HAART. HIV
Med. 2009;10:p89.
48. Dao CN , Patel P, Overton ET. Low Vitamin D Among HIV-Infected
Adults: Prevalence of and Risk Factors For Low Vitamin D Levels in a
Cohort of HIV-Infected Adults and Comparison to Prevalence Among
Universitas Sumatera Utara
58
Adults in The US General Population. Clinical Infectious Disseases.
2011;52:396-405.
49. Harkness L, Cromer B. Low Levels of 25-Hydroxy Vitamin D are
Associated with Elevated Parathyroid Hormone in Healthy Adolescent
Females. Osteoporos Int. 2005;16:109-13.
50. Herzmann C, Arasteh K. Efavirenz Induced Osteomalacia. AIDS.
2009;23:273–78.
51. Vescini F. Vitamin D Deficiency in HIV-Positive Patients. HAART and
Correlated Pathologies. 2010;7:7-11.
52. Zhu J and Paul WE. CD4 T Cells: Fates, Functions, and Faults. Blood.
2008;112: 1557-69.
Universitas Sumatera Utara
DAFTAR PUSTAKA
1. Djoerban Z, Djauzi. HIV/AIDS di Indonesia. Dalam: Buku Ajar Ilmu
Penyakit Dalam, Jilid III, Edisi V, Pusat Penerbit Departemen Ilmu
Penyakit Dalam FKUI, Jakarta: 2009 November; 2861-8.
2. Nasronudin. Penatalaksanaan Klinis Infeksi HIV & AIDS. Dalam: HIV
AIDS, Pendekatan Biologi Molekuler, Klinis dan Sosial. Barakbah J,
Soewandojo E, Suharto, Hardi U, Astuti WD. Universitas Airlangga.
Surabaya: 2007; 31-43.
3.
Fauci AS and Lane HC. Human Immunodeficiency Virus disease: AIDS
and related disorders. In: Kasper DL, Fauci AS, Longo DL, Braunwald
E, Hauser SL, Jameson JL (eds). Harrison’s Principles of Internal
Medicine Volume 1. 17th Edition. New York: Mc Graw Hill Companies.
2008; 1076-98.
4. U.S. Agency for International Development (2010). HIV/AIDS Health
Profile.
http://www.usaid.gov/our_work/global_health/aids/Countries/asia/indone
sia.html
5. United Nations Programme on HIV/AIDS. Global report: UNAIDS report
on the Global AIDS Epidemic 2012.
6. Kementerian
Kesehatan
Republik
Indonesia.
Direktorat
Jenderal
Pengendalian Penyakit dan Penyehatan Lingkungan (Ditjen P2PL).
Laporan Perkembangan HIV/AIDS. 2012.
7. Kementrian Kesehatan Republik Indonesia. Informasi Pengendalian
Penyakit Penyehatan Lingkungan. Direktorat Jenderal Pengendalian
Penyakit dan Penyehatan Lingkungan. 2013.
Universitas Sumatera Utara
54
8. Dinkes
Provinsi
Penanggulangan
Sumatera
Penyakit
Utara.
Kasus
Menular
dan
HIV/AIDS.
penyehatan
Bidang
Lingkungan
(P2MPL). 2013.
9. Mehta S, Giovannuci E, Mugusi FM et al. Vitamin D Status of HIVInfected Women and Its Association with HIV Disease Progression,
Anemia and Mortality. Plos One. 2010; 5:e8770.
10. Kementerian
Kesehatan
Republik
Indonesia.
Direktorat
Jenderal
Pengendalian Penyakit dan Penyehatan Lingkungan (Ditjen P2PL).
Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi
Antiretroviral pada Orang Dewasa dan Remaja. 2011.
11. World Health Organization. Antiretroviral Therapy for HIV Infection in
Adults and Adolescents: Recommendations for a Public Health
Approach. 2010.
12. Holick MF. Vitamin D Deficiency. N Engl J Med. 2007;357:266-8.
13. Holick MF. Sunlight and Vitamin D for Bone Health and Prevention of
Autoimmune Dissease, Cancers, and Cardiovascular Dissease. Am J Clin
Nutr. 2004; 80(suppl):1678S– 88S.
14. Carolien JP, Bos M, Oyen WJG, et al. Vitamin D Deficiency Among
HIV-1-Infected Individuals in The Netherlands: Effects of Antiretroviral
Therapy. Aids Research and Human Retroviruses. 2008; 24: 1375-82.
15. Botella AC, Florence E, Lynen L, et al. Decrease of Vitamin D
Concentration in Patients with HIV Infection on a Non-nucleoside
Reverse transcriptase Inhibitor-Containing regimen. 2010.
16. Melamed ML, Michos ED, Post W, et al. 25-hydroxyl Vitamin D Levels
and Risk Mortaliy in The General Populations. Arch Intern Med. 2008;
168:1629–37.
17. Ellfolk M, Norlin M, Gyllensten, et al. Regulation of Human Vitamin D
(3) 25-Hydroxylases in Dermal Fibroblasts and Protease Cancer LNCaP
Cells. Mol Pharmacol. 2009; 75:1392-99.
18. Paul TV, Asha HS, Thomas N, et al. Hypovitaminosis D and Bone
Mineral Density in Human Immunodeficiency Virus-Infected Men from
Universitas Sumatera Utara
55
India, with or without Antirretroviral Therapy. Endocrine Practice. 2010;
16: 547-53.
19. Cozzolino M, Vidal M, Arcidiacono MV, et al. HIV-Protease Inhibitors
Impair Vitamin D Bioactivation to 1,25-Dihydroxyvitamin D. AIDS.
2003; 17: 513-20.
20. Chorol T, Das S, Choudhry S, Ramachandran VG, Ranga GS,
Bhattacharya SN, Bhadoria DP. Absolute Lymphocyte Count: A useful
Surrogate Marker to Initiate Antiretroviral Therapy in Resource Poor
Settings. Asian Pacific Journal of Tropical Disease. 2012; 744-7.
21. Fauci AS. HIV and AIDS: 20 Years of Science. Nature Medicine. 2008;
9(7): 839-43.
22. Levy JA. HIV Pathogenesis: 25 Years of Progress and Persistent
Challenges. AIDS. 2009; 23: 147-60.
23. Montagnier L. 25 Years After HIV Discovery: Prospects for Cure and
Vaccine. Nobel Lecture, World Foundation for AIDS Research and
Prevention, UNESCO. 2008.
24. Belasio FE, Raimondo M, Suligoi B, Butto S. HIV Virology and
Pathogenetic Mechanism of Infection: A Brief Overview, Ann 1st Super
Sanita. 2010; 46(1):5-14.
25. Liu PT, Stenger S, Tang DH, et al. Cutting Edge: Vitamin D Mediated
Human Antimicrobial Activity Against Mycobacterium Tuberculosis is
Dependent on The Induction of Cathelicidin. J Immunol. 2007;179:206063.
26. World Health Organization, Regional Office for South-East Asia.
Management of HIV Infection and Antiretroviral Therapy in Adults and
Adolescents. A Clinical Manual. 2007.
27. Hadigan C, Meigs JB, Corcoran C, Rietschel P, Piecuch S, Basgoz N, et
al. Metabolic Abnormalities and Cardiovascular Disease Risk Factors in
Adults
With
Human
Immunodeficiency
Virus
Infection
and
Lipodystrophy. Clin Infect Dis. 2001; 32(1):130-9.
Universitas Sumatera Utara
56
28. World Health Organization (b). WHO Case Definitions of HIV and
Revised Clinical Staging and Immunological Clasification of HIVRelated Disease in Adult and Children. 2007.
29. World Health Organization (a). Laboratory Guidelines for Enumerating
CD4 T Lymphocytes in the Context of HIV/AIDS. 2007.
30. Wormster GP. The Epidemiologi of HIV and AIDS in AIDS and Other
Manifestation of HIV Infection. New York: Medical College Villaha.
2005.
31. Carpenter CC, Fischl MA, Hammer SM, Hirsch MS, Jacobsen DM,
Katzenstein DA, et al. Antiretroviral Therapy for HIV Infection in 1996.
Recommendations of an
International
Panel.
International
AIDS
Society-USA.
JAMA.
1996;276(2):46-54.
32. Max B, Sherer R. Management of The Adverse of Antiretroviral Therapy
and Medication Adherence. Clinical Infection Disease. 2000;30 (Suppl
2): S96-116.
33. Ammassari A, Antinori A, Cozzi-Lepri A, Trotta MP, Nasti G, Ridolfo
AL, et al.
Relationship
Between
HAARTAdherence
and
Adipose
Tissue
Alterations. J Acquir Immune Defic Syndr 2002;31 (Suppl 3):140-4.
34. Jagriti P. Pharmacokinetic Boosting of Zidovudine for HIV Treatment,
Int J of Pharmac and Clin Research. 2012;4(3):31-6.
35. Bouvier G. Protease Inhibitors Can Interfere With Vitamin D
Metabolism. HIV Clinician. 2009;9-10.
36. Hewison M. Vitamin D, Immunity and Human Disease. Clinical Rev
Bone Miner Metabolit. 2010;8:32-39.
37. Adams JS, Liu PT, Chun R, et al. Cutting edge: Vitamin in Defense of
Human Immune Response. Ann N Y Acad Sci. 2007; 1117: 94-105.
38. Rosen CJ. Vitamin D insufficiency. N Engl J Med. 2011;364:248-54
39. Haug
JC,
Aukrust
P,
Haug
E.
Severe
Deficiency of
1,25-
Dihydroxyvytamin D 3 in Human Immunodeficiency Virus Infection:
Universitas Sumatera Utara
57
Association With Immunological Hyperactivity and Only Minor Changes
in Calcium Homeostasis. JCE&M. 1998;83:3832-38.
40. Direktorat Jenderal Pemberantasan Penyakit Menular dan Penyehatan
Lingkungan, Departemen Kesehatan Republik Indonesia. Pedoman
Nasional Perawatan, Dukungan dan Pengobatan Bagi ODHA. Jakarta.
Dep Kes RI. 2003.
41. Spaulding A, Rutherford GW, Siegfried N. Tenofovir or Zidovudine in
Three-Drug Combination Therapy with One Nucleoside Reverse
Transcriptase Inhibitor and One Non-Nucleoside Reverse Transcriptase
Inhibitor for Initial Treatment of HIV Infection in Antiretroviral-Naive
Individuals. Wiley. Cochrane Collaboration. 2011;2:1-28.
42. Ramayo E, Moreno MPG, Macias J, et al. Relationship Between
Osteopenia, Free Testosterone, and Vitamin D Metabolite Levels in HIVInfected Patients With and Without Highly Active Antiretroviral Therapy.
AIDS Research and Human Retroviruses. 2005;2:915-21.
43. Liz H et al. Vitamin D Deficiency is Common Among HIV Positive
People and Is Associated with NNRTI Use, Black Race and Sunning.
2009.
44. Viard JP et al. Vitamin D and Clinical Disease Progression in HIV
Infection: Results from The EuroSIDA Study. AIDS. 2011.
45. Chakborty H, Newman JE, Woelk G, Foday H, Peres JI. Antiretroviral
Therapy Initiation and CD4 Progression Over time Among HIV Infected
Adults in Centra Africa. Int J of Med and Public Health. 2011; 1(4):3-11.
46. Gazzard B. What We Know So Far. AIDS. 1996;10(Suppl 1):S3-7.
47. Childs K, Kadis C, Baranch-Elliman W. Vitamin D and Calcium
Supplements
Reverse
The
Secondary
Hyperparathyroidsm
That
Commonly Occurs in HIV Patients on TDF-Containing HAART. HIV
Med. 2009;10:p89.
48. Dao CN , Patel P, Overton ET. Low Vitamin D Among HIV-Infected
Adults: Prevalence of and Risk Factors For Low Vitamin D Levels in a
Cohort of HIV-Infected Adults and Comparison to Prevalence Among
Universitas Sumatera Utara
58
Adults in The US General Population. Clinical Infectious Disseases.
2011;52:396-405.
49. Harkness L, Cromer B. Low Levels of 25-Hydroxy Vitamin D are
Associated with Elevated Parathyroid Hormone in Healthy Adolescent
Females. Osteoporos Int. 2005;16:109-13.
50. Herzmann C, Arasteh K. Efavirenz Induced Osteomalacia. AIDS.
2009;23:273–78.
51. Vescini F. Vitamin D Deficiency in HIV-Positive Patients. HAART and
Correlated Pathologies. 2010;7:7-11.
52. Zhu J and Paul WE. CD4 T Cells: Fates, Functions, and Faults. Blood.
2008;112: 1557-69.
Universitas Sumatera Utara